pdufa.bio
Home › Decisions › PFE 2026-05-01

PFE FDA decision — May 1, 2026

✓ APPROVED

Pfizer Inc. — VEPPANU (vepdegestrant) - (VERITAC-2) · Breast cancer.

Run-up into the decision (T-120 → T+5)

PDUFA 5/1/26$28.55$24.3911/14/25
Daily close, T-120 (11/14/25) through T+5. Run-up high $28.55 on 4/2/26, low $24.39 on 11/18/25 (T-120 to T-1). FDA decision 5/1/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-05-01
OutcomeApproved
Drug / candidateVEPPANU (vepdegestrant) - (VERITAC-2)
CompanyPfizer Inc.
120-day run-up (T-120→T-1)+7.4%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio